Brief: SELLAS Life Sciences FY Net Income USD -30.881 Million
Brief: Sellas Life Sciences Says Full Topline Phase 2 Data In Acute Myeloid Leukemia And FDA Regulatory Review Expected In 1H 2025 For SLS009
Sellas rises on preclinical data for blood cancer drug
Brief: Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers
Sellas Life Sciences Group Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: SELLAS Life Sciences Q3 Net Income USD -7.108 Million
Sellas Life Sciences Group Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: SELLAS Life Sciences Q2 Net Income USD -7.47 Million
Sellas Life Sciences Group Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
Brief: Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted To SLS009 For The Treatment Of Pediatric Acute Lymphoblastic Leukemia
Advisory: Alert from FN Media Group wrongly tagged to multiple companies withdrawn
Brief: Sellas Life Sciences Announces Positive Recommendation From Data Monitoring Committee Of Phase 3 Trial In Acute Myeloid Leukemia
Brief: SELLAS Life Sciences Q1 Net Income USD -9.566 Million
Sellas Life Sciences Group Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: SELLAS Life Sciences Announces Independent Data Monitoring Committee Post Completion Of Enrollment In Regal Phase III Study
Sellas Life Sciences Group Inc reports results for the quarter ended in December - Earnings Summary
Brief: Sellas Life Sciences Group Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Brief: Sellas Life Sciences Announces Closing Of $20 Million Registered Direct Offering And Concurrent Private Placement